286 related articles for article (PubMed ID: 31009315)
21. Phosphorothioate modification of chimeric 2´-O-methyl RNA/ethylene-bridged nucleic acid oligonucleotides increases dystrophin exon 45 skipping capability and reduces cytotoxicity.
Malueka RG; Dwianingsih EK; Yagi M; Lee T; Nishida A; Iijima K; Takeshima Y; Matsuo M
Kobe J Med Sci; 2015 Feb; 60(4):E86-94. PubMed ID: 25791417
[TBL] [Abstract][Full Text] [Related]
22. Cyclic Peptides to Improve Delivery and Exon Skipping of Antisense Oligonucleotides in a Mouse Model for Duchenne Muscular Dystrophy.
Jirka SMG; 't Hoen PAC; Diaz Parillas V; Tanganyika-de Winter CL; Verheul RC; Aguilera B; de Visser PC; Aartsma-Rus AM
Mol Ther; 2018 Jan; 26(1):132-147. PubMed ID: 29103911
[TBL] [Abstract][Full Text] [Related]
23. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
[TBL] [Abstract][Full Text] [Related]
24. Oligonucleotide Enhancing Compound Increases Tricyclo-DNA Mediated Exon-Skipping Efficacy in the Mdx Mouse Model.
Bizot F; Fayssoil A; Gastaldi C; Irawan T; Phongsavanh X; Mansart A; Tensorer T; Brisebard E; Garcia L; Juliano RL; Goyenvalle A
Cells; 2023 Feb; 12(5):. PubMed ID: 36899837
[TBL] [Abstract][Full Text] [Related]
25. Morpholino-induced exon skipping stimulates cell-mediated and humoral responses to dystrophin in mdx mice.
Vila MC; Novak JS; Benny Klimek M; Li N; Morales M; Fritz AG; Edwards K; Boehler JF; Hogarth MW; Kinder TB; Zhang A; Mazala D; Fiorillo AA; Douglas B; Chen YW; van den Anker J; Lu QL; Hathout Y; Hoffman EP; Partridge TA; Nagaraju K
J Pathol; 2019 Jul; 248(3):339-351. PubMed ID: 30883742
[TBL] [Abstract][Full Text] [Related]
26. Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides.
Echigoya Y; Yokota T
Nucleic Acid Ther; 2014 Feb; 24(1):57-68. PubMed ID: 24380394
[TBL] [Abstract][Full Text] [Related]
27. Systematic evaluation of 2'-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro.
Chen S; Le BT; Chakravarthy M; Kosbar TR; Veedu RN
Sci Rep; 2019 Apr; 9(1):6078. PubMed ID: 30988454
[TBL] [Abstract][Full Text] [Related]
28. Approaches for Systemic Delivery of Dystrophin Antisense Peptide Nucleic Acid in the mdx Mouse Model.
Brolin C; Lim EWK; Grizot S; Olsen CH; Yavari N; Krag TO; Nielsen PE
Nucleic Acid Ther; 2021 Jun; 31(3):208-219. PubMed ID: 32678992
[TBL] [Abstract][Full Text] [Related]
29. Systemic administration of the antisense oligonucleotide NS-065/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy.
Komaki H; Nagata T; Saito T; Masuda S; Takeshita E; Sasaki M; Tachimori H; Nakamura H; Aoki Y; Takeda S
Sci Transl Med; 2018 Apr; 10(437):. PubMed ID: 29669851
[TBL] [Abstract][Full Text] [Related]
30. Control of backbone chemistry and chirality boost oligonucleotide splice switching activity.
Kandasamy P; McClorey G; Shimizu M; Kothari N; Alam R; Iwamoto N; Kumarasamy J; Bommineni GR; Bezigian A; Chivatakarn O; Butler DCD; Byrne M; Chwalenia K; Davies KE; Desai J; Shelke JD; Durbin AF; Ellerington R; Edwards B; Godfrey J; Hoss A; Liu F; Longo K; Lu G; Marappan S; Oieni J; Paik IH; Estabrook EP; Shivalila C; Tischbein M; Kawamoto T; Rinaldi C; Rajão-Saraiva J; Tripathi S; Yang H; Yin Y; Zhao X; Zhou C; Zhang J; Apponi L; Wood MJA; Vargeese C
Nucleic Acids Res; 2022 Jun; 50(10):5443-5466. PubMed ID: 35061895
[TBL] [Abstract][Full Text] [Related]
31. Antisense oligonucleotide drugs for Duchenne muscular dystrophy: how far have we come and what does the future hold?
Guncay A; Yokota T
Future Med Chem; 2015; 7(13):1631-5. PubMed ID: 26423833
[No Abstract] [Full Text] [Related]
32. Antisense Oligonucleotides Conjugated with Lipophilic Compounds: Synthesis and In Vitro Evaluation of Exon Skipping in Duchenne Muscular Dystrophy.
Marchesi E; Cortesi R; Preti L; Rimessi P; Sguizzato M; Bovolenta M; Perrone D
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457088
[TBL] [Abstract][Full Text] [Related]
33. Intraperitoneal administration of phosphorothioate antisense oligodeoxynucleotide against splicing enhancer sequence induced exon skipping in dystrophin mRNA expressed in mdx skeletal muscle.
Takeshima Y; Yagi M; Wada H; Matsuo M
Brain Dev; 2005 Oct; 27(7):488-93. PubMed ID: 16198206
[TBL] [Abstract][Full Text] [Related]
34. Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases.
Tsoumpra MK; Fukumoto S; Matsumoto T; Takeda S; Wood MJA; Aoki Y
EBioMedicine; 2019 Jul; 45():630-645. PubMed ID: 31257147
[TBL] [Abstract][Full Text] [Related]
35. Lowering Mutant Huntingtin Using Tricyclo-DNA Antisense Oligonucleotides As a Therapeutic Approach for Huntington's Disease.
Imbert M; Blandel F; Leumann C; Garcia L; Goyenvalle A
Nucleic Acid Ther; 2019 Oct; 29(5):256-265. PubMed ID: 31184975
[TBL] [Abstract][Full Text] [Related]
36. Using a State-of-the-Art Toolbox to Evaluate Molecular and Functional Readouts of Antisense Oligonucleotide-Induced Exon Skipping in
Datson NA; Bijl S; Janson A; Testerink J; van den Eijnde R; Weij R; Puoliväli J; Lehtimäki K; Bragge T; Ahtoniemi T; van Deutekom JC
Nucleic Acid Ther; 2020 Feb; 30(1):50-65. PubMed ID: 31821107
[TBL] [Abstract][Full Text] [Related]
37. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
[TBL] [Abstract][Full Text] [Related]
38. Designing Effective Antisense Oligonucleotides for Exon Skipping.
Shimo T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of Multi-exon Skipping Treatment in Duchenne Muscular Dystrophy Dog Model Neonates.
Lim KRQ; Echigoya Y; Nagata T; Kuraoka M; Kobayashi M; Aoki Y; Partridge T; Maruyama R; Takeda S; Yokota T
Mol Ther; 2019 Jan; 27(1):76-86. PubMed ID: 30448197
[TBL] [Abstract][Full Text] [Related]
40. Towards a therapeutic inhibition of dystrophin exon 23 splicing in mdx mouse muscle induced by antisense oligoribonucleotides (splicomers): target sequence optimisation using oligonucleotide arrays.
Graham IR; Hill VJ; Manoharan M; Inamati GB; Dickson G
J Gene Med; 2004 Oct; 6(10):1149-58. PubMed ID: 15386737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
